Tuesday, December 05, 2023
  1. You Are At:
  2. English News
  3. Health
  4. Blood test that can detect breast cancer available in India now, know the cost

Blood test that can detect breast cancer available in India now, know the cost

A blood test that can detect early stages of breast cancer in patients with 99 per cent accuracy will cost Rs 6000 in India. Those who test positive can proceed with screening and treatment.

Health Desk Written by: Health Desk New Delhi Updated on: June 22, 2022 22:45 IST
Image Source : FREEPIK

image representing blood test

A blood test proven to detect breast cancer in the early stages has been made available in India. The test is available in more than 15 countries worldwide and can detect stage 0 and stage 1 of breast cancer in women with 99 per cent accuracy. As per reports, the blood test can help in detecting breast cancer at an early stage for those who are above 40 years of age. 

Cost in India

The test, being branded as EasyCheck Breast, will cost Rs 6,000. It was approved by the US Food and Drug Administration in November last year and is indicated as an annual test for healthy women above the age of 40 years who may not have any symptoms. The study has shown stage 0 and stage 1 breast cancer cases were detected with an accuracy of 99 per cent. 

Read: Men's Health Month: Prostate cancer in younger men on the rise, know early signs, treatment

Blood test to help women detect breast cancer 

"It's not the replacement of mammograms but women who test positive for breast cancer using the new technology can go for conventional screening examinations and can straight away go for a biopsy and plan their treatment for cancer," said a doctor, who further suggested that if a women tests negative, then also she should go for other screening tests to rule out breast cancer completely. 

Gene drug that improves breast cancer patients' survival rate

Meanwhile, the results of a study published in the Lancet Oncology journal showed the breast cancer patients who were given Capivasertib, developed by AstraZeneca, survived almost twice as long than those given the standard treatment alone. "There has never been a trial targeting this genetic pathway in breast cancer that has an overall survival advantage like this - it's really quite extraordinary," Prof Rob Jones, of Velindre Cancer Centre and Cardiff University, was quoted as saying.

Read: Not just mothers but postpartum depression affects dads too

(With inputs from news agencies)

Latest Health News

Read all Assembly Election Results 2023 Live on indiatvnews.com and Get the Latest English News and Updates on Madhya Pradesh, Chhattisgarh, Mizoram, Rajasthan and Telangana